Tilray, inc. supports new clinical trial evaluating the efficacy of medical cannabis in disorders caused by breast cancer treatment

Tilray, inc. announced it has successfully imported medical cannabis into the united states from canada in support of a new clinical trial. the study will test the efficacy of medical cannabis in treating patients with breast cancer who are suffering from taxane-induced peripheral neuropathy (tipn) secondary to treatment with paclitaxel or docetaxel. this clinical trial is the first human study testing the effectiveness of medical cannabis to treat tipn. led by diana martinez, m.d., professor of psychiatry at columbia university irving medical center (cuimc), and margaret haney, ph.d., professor of neurobiology (in psychiatry) at cuimc, the clinical trial will be a randomized placebo-controlled study in which half of participants will receive an investigational product containing a combination of thc and cbd and the other half will receive a product with no active cannabinoids. participants will be treated twice daily for eight weeks. researchers are currently recruiting patients for the study. tipn affects more than 67% of women undergoing breast cancer treatment. as a result of tipn, some patients must shorten their course of treatment and are unable to reap the full benefits of chemotherapy. although currently there is a lack of effective treatment for tipn, studies assessing the use of medical cannabis to treat paclitaxel-induced neuropathic pain in mice have demonstrated positive results.
TLRY Ratings Summary
TLRY Quant Ranking